Cargando…

Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta‐analysis of randomized control trials

AIMS/INTRODUCTION: Canagliflozin has been proposed as an effective treatment for type 2 diabetes. This meta‐analysis of randomized control trials aimed to evaluate the effect of canagliflozin combined with other hypoglycemic drugs. MATERIALS AND METHODS: We searched Medline, Embase, Cochrane Library...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Qi, Shen, Yun, Liu, Dajin, Jiang, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847890/ https://www.ncbi.nlm.nih.gov/pubmed/27330722 http://dx.doi.org/10.1111/jdi.12417

Ejemplares similares

Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin
por: Papadopoli, David, et al.
Publicado: (2021)

Efficacy and Safety of Oral Antidiabetic Drugs in Comparison to Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis
por: Poolsup, Nalinee, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
por: Xiong, Wei, et al.
Publicado: (2016)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
por: Prasanna Kumar, K. M., et al.
Publicado: (2016)

Management of diabetes mellitus in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
por: Sehgal, Vishal, et al.
Publicado: (2014)

Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis
por: Liang, Hui-ling, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis
por: Kaur, Kirandeep, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2018)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
por: John, Mathew, et al.
Publicado: (2016)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
por: Fulcher, Greg, et al.
Publicado: (2015)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
por: Zhou, Zien, et al.
Publicado: (2019)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
por: Baruah, Manash P., et al.
Publicado: (2016)

Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
por: Buysman, Erin K., et al.
Publicado: (2015)

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
por: Adachi, Junichiro, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Stenlöf, K, et al.
Publicado: (2013)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
por: Nardolillo, AnneMarie, et al.
Publicado: (2014)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
por: Signorovitch, J E, et al.
Publicado: (2013)

Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis
por: Jia, Yongliang, et al.
Publicado: (2015)

Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy
por: Kutoh, Eiji, et al.
Publicado: (2017)

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Sinclair, Alan J., et al.
Publicado: (2016)

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
por: Prasanna Kumar, K. M., et al.
Publicado: (2017)

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
por: Qiu, Rong, et al.
Publicado: (2016)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
por: Davies, M. J., et al.
Publicado: (2015)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
por: Wang, Limin, et al.
Publicado: (2023)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice
por: Zhu, Qian, et al.
Publicado: (2023)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7mnv82di196cmck08uufh9s8ou